CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 393 enrolled
Drug / intervention
Valsartan/amlodipine 80/5 mg tablets +4 moredrug
Likely dose
Valsartan/amlodipine 80/5 mg tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00687973
NCT00687973Phase 4Completed
CompareCT.gov

Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg

Novartis Pharmaceuticals·interventional·Posted Jun 2, 2008·Updated Mar 11, 2011

In Brief

A Phase 4 clinical trial evaluating Valsartan/amlodipine 80/5 mg tablets, Amlodipine 5 mg capsules, and 3 other interventions for Hypertension. Completed, enrolled 393 participants across 1 site.

Detailed Summary

Assess that for an equivalent brachial blood pressure (BP)lowering, a fixed dose combination amlodipine/valsartan based regimen reduces central aortic BP pressure to a larger extent than an atenolol/amlodipine combination based regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesFrance
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2, 2008
Enrollment StartJan 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.1 years ago

Interventions

Valsartan/amlodipine 80/5 mg tabletsdrug

Amlodipine 5 mg capsulesdrug

Amlodipine 10 mg capsulesdrug

Atenolol 50 mg tabletsdrug

Atenolol 100 mg tabletsdrug